Cue Biopharma has entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $50 million. The company will sell 1,418,071 shares of common stock at $33.21 per share, and certain investors will receive pre-funded warrants to purchase up to 87,500 shares at $33.209 per warrant. The pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable. The private placement is led by Cormorant Asset Management with participation from Columbia Threadneedle Investments and is expected to close on or about July 13, 2026, subject to customary closing conditions. Cue Biopharma intends to use the net proceeds to advance clinical development and for general corporate purposes, and it highlighted upcoming data from a Phase 2 study of CUE-221 in chronic spontaneous urticaria expected by the end of the third quarter of 2026.
Cue BiopharmaCue Biopharma raises $50M via private placement to fund clinical development.